Vascular tone control in humans: Insights from studies in Bartter's/Gitelman's syndromes

Kidney International

Volumn 69, Issue 6, 2006, Pages 963-966

  Calo L A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiotensin II signaling; Hypertension; Rho kinase

Indexed keywords

ANGIOTENSIN II; GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE; RGS PROTEIN; RHO KINASE;

ATHEROGENESIS; BARTTER SYNDROME; BIOCHEMISTRY; BLOOD VESSEL REMODELING; BLOOD VESSEL TONE; DISEASE MODEL; GITELMAN SYNDROME; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE STRUCTURE;

ANGIOTENSIN II; BARTTER SYNDROME; BLOOD PRESSURE; BLOOD VESSELS; CALCIUM; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; GTP-BINDING PROTEINS; HUMANS; HYPERTENSION; HYPERTROPHY; JUXTAGLOMERULAR APPARATUS; MAGNESIUM; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SYNDROME;

EID: 33644871442     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000253     Document Type: Short Survey

References (49)

1. Touyz RM. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5: 155-164.
2. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001; 37: 1047-1052.
3. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361: 315-325.
4. Davis Mj, Hill MH. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 70: 387-423.
5. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
6. 2+ homeostasis. Biochem Pharmacol 1998; 55: 713-718.
7. Calò L, Davis PA, Semplicini A. Regulation of vascular tone in Bartter's and Gitelman's syndromes. Crit Rev Clin Lab Sci 2000; 37: 503-523.
8. Calò LA, Pessina AC, Semplicini A. Angiotensin ii signaling in the Bartter's and Gitelman's syndromes, a negative human model of hypertension. High Blood Press Cardiovasc Prev 2005; 12: 17-26.
9. Naesens M, Steels P, Verberckmoes R et al. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol 2004; 96: 65-78.
10. Calò L, Davis PA, Semplicini A. Bartter's/Gitelman's syndrome: a model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. Clin Nephrol 2003; 59: 393-394.
11. 11, protein signaling in vascular myocites. Trends Cardiovasc Med 1998; 8: 157-162.
12. Anand-Srivastava MB. Angiotensin II receptors negatively coupled to adenylate cyclase in rat aorta. Biochem Biophys Res Commun 1983; 117: 420-428.
13. Sward K, Mita M, Wilson DP et al. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5: 66-72.
14. Anand-Srivastava MB. Angiotensin II receptors negatively coupled to adenylate cyclase in rat myocardial sarcolemma. Involvement of inhibitory guanine nucleotide regulatory protein. Biochem Pharmacol 1989; 38: 489-496.
15. Fukata Y, Amano M, Kaibuki K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22: 32-39.
16. Calò L, Ceolotto G, Milani M et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60: 882-889.
17. Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61: 353-354.
18. Di Virgilio F, Calò L, Cantaro S et al. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clin Sci 1987; 72: 483-488.
19. Calo L, D'Angelo A, Cantaro S et al. Intracellular calcium signalling and vascular reactivity in Bartter's syndrome. Nephron 1996; 72: 570-573.
20. Pagnin E, Davis PA, Sartori M et al. Rho kinase and PAI-1 in Bartter's/ Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22: 1963-1969.
21. Calò L, Davis PA, Milani M et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51: 12-17.
22. - and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 874-879.
23. Wolfrum S, Dendorfer A, Rikitake Y et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842-1847.
24. Mita S, Kobayashi N, Yoshida K et al. Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 2005; 23: 87-96.
25. Calò LA, Pagnin E, Davis PA et al. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18: 1518-1525.
26. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-554.
27. Martin D, Rojo AI, Saunas M et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004; 279: 8919-8929.
28. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G-proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-1358.
29. Sah PV, Seasholtz MT, Sagi AS, Brown HJ. The role of Rho in G protein-coupled receptor signal transduction. Annu Rev Pharmacol Toxicol 2000; 40: 459-489.
30. Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69: 795-827.
31. Ying Z, Jin L, Dorrance AM, Webb RC. Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 2004; 17: 981-985.
32. Hepler RJ. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999; 20: 376-382.
33. Zhong H, Neubig RR. Regulator of G protein signalling proteins; novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297: 837-845.
34. Heximer SP, Knutsen RH, Sun X et al. Hypertension and prolonged vasoconstrictor signalling in RGS2-deficient mice. J Clin Invest 2003; 111: 445-452.
35. Tang M, Wang G, Lu P et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9: 1506-1512.
36. Li Y, Hashim S, Anand-Srivastava MB. Angiotensin II-evoked enhanced expression of RGS2 attenuates Gi-mediated adenylyl cyclase signaling in A10 cells. Cardiovasc Res 2005; 66: 503-511.
37. Calò LA, Pagnin E, Davis PA et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89: 4153-4157.
38. Sartori M, Lenzini L, Papparella I et al. RGS2 expression and intracellular calcium mobilization in fibroblasts from hypertensive patients. J Hypertens 2004; 22(Suppl 2): S146-S147.
39. Baritono E, Ceolotto G, Papparella I et al. Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals. J Hypertens 2004; 22: 783-792.
40. Stoff JS, Stemerman M, Steer M et al. A defect in platelet aggregation in Bartter's syndrome. Am J Med 1980; 68: 171-180.
41. Pagnin E, Semplicini A, Sartori M et al. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes. Relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18: 1200-1205.
42. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation 2003; 108: 2034-2040.
43. Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
44. Nath KA, Grande J, Croatt A et al. Redox regulation of renal DNA synthesis, transforming growth factor-beta-1 and collagen gene expression. Kidney Int 1998; 53: 367-381.
45. Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 1998; 8: 59-64.
46. Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol 2000; 60: 1121-1128.
47. Calò L, Sartore G, Bassi A et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16: 1001-1008.
48. Calò LA, Pagnin E, Sartori M et al. Bartter's and Gitelman's syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection. J Hypertens 2005; 23: 1273-1275.
49. Calo LA, Pagnin E, Davis PA et al. Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome. Arterioscler Thromb Vasc Biol 2005; 25: e34.